https://scholars.lib.ntu.edu.tw/handle/123456789/537447
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | WAN-YU CHEN | en_US |
dc.contributor.author | CHUN-WEI WANG | en_US |
dc.contributor.author | Chang C.-H. | en_US |
dc.contributor.author | Liu H.-H. | en_US |
dc.contributor.author | KENG-HSUEH LAN | en_US |
dc.contributor.author | JIH-LUH TANG | en_US |
dc.contributor.author | HWEI-FANG TIEN | en_US |
dc.contributor.author | SUNG-HSIN KUO | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.date.accessioned | 2021-01-04T12:12:40Z | - |
dc.date.available | 2021-01-04T12:12:40Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1748-717X | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84886891610&doi=10.1186%2f1748-717X-8-245&partnerID=40&md5=a9b621f18ef0eb801c569eba12305f83 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/537447 | - |
dc.description.abstract | Background: To evaluate clinicopathological features, radiotherapeutic parameters, and their associations with responses to radiotherapy (RT) in patients with myeloid sarcoma (MS).Methods: We reviewed 20 patients receiving RT for MS lesions (in 43 RT courses) and analyzed the patients' clinicopathologic features and radiotherapeutic parameters, and their associations with complete responses (CR) to RT using Fisher's exact test and univariate logistic regression analysis. Generalized Estimating Equation was used to analyze all 43 irradiated lesions and account for the correlations in RT responses among lesions from the same patient.Results: We found that the underlying hematological diseases of the evaluated patients were acute myeloid leukemia (AML) in 14 patients (70%), chronic myeloid leukemia in 4 patients (20%), myelodysplastic syndrome with AML transformation in one patient (5%), and de novo MS in one patient (5%). Most patients (55%) received RT for MS at the time of relapse following bone marrow transplantation (BMT). The most common cytogenetic abnormality was t(8;21)(q22;q22). The median RT dose of 20 Gy (range 6-35 Gy), administered in 1.5-3.5 Gy fractions, provided a 63% CR rate. RT dose, sex, cytogenetics, and bone marrow status at the time of RT had no significant effect on CR. Younger age (<50 y, P = 0.06), BMT prior to RT (P = 0.05), and underlying AML (P = 0.05) were marginally associated with higher CR to RT.Conclusions: Our results indicate that a modest RT dose (20-30 Gy) achieves good local control of MS. Age, previous BMT, and underlying hematologic disease can affect RT response. ? 2013 Chen et al.; licensee BioMed Central Ltd. | - |
dc.relation.ispartof | Radiation Oncology | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | antineoplastic agent; acute granulocytic leukemia; adolescent; adult; age; aged; article; bone marrow transplantation; cancer chemotherapy; cancer control; cancer palliative therapy; cancer patient; cancer radiotherapy; cancer surgery; cancer survival; chemosurgery; child; chronic myeloid leukemia; clinical article; clinical feature; controlled study; correlational study; cytogenetics; female; granulocytic sarcoma; histopathology; human; leukemia relapse; male; multimodality cancer therapy; myelodysplastic syndrome; preschool child; radiation dose fractionation; retrospective study; school child; treatment response; Kaplan Meier method; middle aged; mortality; pathology; Sarcoma, Myeloid; treatment outcome; very elderly; young adult; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Sarcoma, Myeloid; Treatment Outcome; Young Adult | - |
dc.title | Clinicopathologic features and responses to radiotherapy of myeloid sarcoma | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1186/1748-717X-8-245 | - |
dc.identifier.pmid | 24148102 | - |
dc.identifier.scopus | 2-s2.0-84886891610 | - |
dc.relation.journalvolume | 8 | - |
dc.relation.journalissue | 1 | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Radiology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Radiation Oncology-NTUCC | - |
crisitem.author.dept | Division of Radiation Oncology | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.orcid | 0000-0002-2483-8292 | - |
crisitem.author.orcid | 0000-0002-2758-6027 | - |
crisitem.author.orcid | 0000-0002-1575-5620 | - |
crisitem.author.orcid | 0000-0003-4021-3281 | - |
crisitem.author.orcid | 0000-0002-1384-5593 | - |
crisitem.author.orcid | 0000-0003-0054-887X | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | Oncology-NTUH | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。